ARIPIPRAZOLE

Brand name:

• Abilify Asimtufii®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Lundbeck Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Long acting injectable form of aripiprazole for schizophrenia

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New listing (–)

Comment:

--

Other PBAC consideration:

• ARIPIPRAZOLE

Submission received for:

December 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 13/12/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

24/01/2025

Lodgement of required documentation:

12/02/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 18/02/2025

Status:

Finalised

Government processes:

Commenced on 26/02/2025

Medicine listed on the PBS:

01/05/2025 (see PBS schedule)